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Introduction
The  value  of  molecular  methods  for  cancer  medicine 
stems  from  the  enormous  breadth  of  information  that 
can be obtained from a single tumor sample. Microarrays 
assess  thousands  of  transcripts,  or  millions  of  single 
nucleotide polymorphisms (SNPs), and next-generation 
sequencing (NGS) can reveal copy number and genetic 
aberrations  at  base  pair  resolution.  However,  because 
most applications require bulk DNA or RNA from over 
100,000  cells,  they  are  limited  to  providing  global 
information  on  the  average  state  of  the  population  of 
cells.  Solid  tumors  are  complex  mixtures  of  cells 
including  non-cancerous  fibroblasts,  endothelial  cells, 
lymphocytes,  and  macrophages  that  often  contribute 
more than 50% of the total DNA or RNA extracted. This 
admixture can mask the signal from the cancer cells and 
thus complicate the inter- and intra-tumor comparisons, 
which are the basis of molecular classification methods.
In  addition,  solid  tumors  are  often  composed  of 
multiple  clonal  subpopulations  [1-3],  and  this 
heterogeneity further confounds the analysis of clinical 
samples. Single-cell genomic methods have the capacity 
to  resolve  complex  mixtures  of  cells  in  tumors.  When 
multiple clones are present in a tumor, molecular assays 
reflect  an  average  signal  of  the  population,  or, 
alternatively,  only  the  signal  from  the  dominant  clone, 
which may not be the most malignant clone present in 
the  tumor.  This  becomes  particularly  important  as 
molecular  assays  are  employed  for  directing  targeted 
therapy,  as  in  the  use  of  ERBB2  (Her2-neu)  gene 
amplification  to  identify  patients  likely  to  respond  to 
Herceptin  (trastuzumab)  treatment  in  breast  cancer, 
where 5% to 30% of all patients have been reported to 
exhibit such genetic heterogeneity [4-7].
Aneuploidy is another hallmark of cancer [8], and the 
genetic  lineage  of  a  tumor  is  indelibly  written  in  its 
genomic profile. While whole genomic sequencing of a 
single cell is not possible using current technology, copy 
number profiling of single cells using sparse sequencing 
or  microarrays  can  provide  a  robust  measure  of  this 
genomic complexity and insight into the character of the 
tumor. This is evident in the progress that has been made 
in many studies of single-cell genomic copy number [9-
14]. In principle, it should also be possible to obtain a 
partial representation of the transcriptome from a single 
cell by NGS and a few successes have been reported for 
whole transcriptome analysis in blastocyst cells [15,16]; 
however, as yet, this method has not been successfully 
applied to single cancer cells.
The clinical value of single-cell genomic methods will 
be  in  profiling  scarce  cancer  cells  in  clinical  samples, 
monitoring CTCs, and detecting rare clones that may be 
resistant to chemotherapy (Figure 1). These applications 
are likely to improve all three major themes of oncology: 
detection,  progression,  and  prediction  of  therapeutic 
efficacy. In this review, we outline the current methods 
and those in development for isolating single cells and 
analyzing their genomic profile, with a particular focus 
on profiling genomic copy number.
Abstract
Advances in whole genome amplification and next-
generation sequencing methods have enabled genomic 
analyses of single cells, and these techniques are now 
beginning to be used to detect genomic lesions in 
individual cancer cells. Previous approaches have been 
unable to resolve genomic differences in complex 
mixtures of cells, such as heterogeneous tumors, despite 
the importance of characterizing such tumors for 
cancer treatment. Sequencing of single cells is likely to 
improve several aspects of medicine, including the early 
detection of rare tumor cells, monitoring of circulating 
tumor cells (CTCs), measuring intratumor heterogeneity, 
and guiding chemotherapy. In this review we discuss 
the challenges and technical aspects of single-cell 
sequencing, with a strong focus on genomic copy 
number, and discuss how this information can be used 
to diagnose and treat cancer patients.
© 2010 BioMed Central Ltd
Future medical applications of single-cell 
sequencing in cancer
Nicholas Navin*1,2 and James Hicks3
REVIEW
*Correspondence: navin@mdanderson.org 
1Department of Genetics, MD Anderson Cancer Center, Houston, TX 77030, USA
Full list of author information is available at the end of the article
Navin and Hicks Genome Medicine 2011, 3:31 
http://genomemedicine.com/content/3/5/31
© 2011 BioMed Central LtdBackground
Although genomic profiling by microarray comparative 
genomic hybridization (aCGH) has been in clinical use 
for constitutional genetic disorders for some time, its use 
in  profiling  cancers  has  been  largely  limited  to  basic 
research.  Its  potential  for  clinical  utility  is  yet  to  be 
realized.  Specific  genomic  events  such  as  Her2-neu 
amplification  as  a  target  for  Herceptin  are  accepted 
clinical  markers,  and  genome-wide  profiling  for  copy 
number  has  been  used  only  in  preclinical  studies  and 
only  recently  been  incorporated  into  clinical  trial 
protocols  [17].  However,  in  cohort  studies,  classes  of 
genomic  copy  number  profiles  of  patients  have  shown 
strong correlation with patient survival [18,19]. Until the 
breakthrough  of  NGS,  the  highest  resolution  for 
identifying copy number variations was achieved through 
microarray-based  methods,  which  could  detect 
amplifications  and  deletions  in  cancer  genomes,  but 
could  not  discern  copy  neutral  alterations  such  as 
translocations  or  inversions.  NGS  has  changed  the 
perspective on genome profiling, since DNA sequencing 
has the potential to identify structural changes, including 
gene  fusions  and  even  point  mutations,  in  addition  to 
copy  number.  However,  the  cost  of  profiling  a  cancer 
genome at base pair resolution remains out of range for 
routine clinical use, and calling mutations is subject to 
ambiguities  as  a  result  of  tumor  heterogeneity,  when 
DNA is obtained from bulk tumor tissue. The application 
of NGS to genomic profiling of single cells developed by 
the  Wigler  group  and  Cold  Spring  Harbor  Lab  and 
described here has the potential to not only acquire an 
even greater level of information from tumors, such the 
variety  of  cells  present,  but  further  to  obtain  genetic 
information  from  the  rare  cells  that  may  be  the  most 
malignant.
Isolating single cells
To study a single cell it must first be isolated from cell 
culture  or  a  tissue  sample  in  a  manner  that  preserves 
biological  integrity.  Several  methods  are  available  to 
accomplish  this,  including  micromanipulation,  laser-
capture  microdissection  (LCM)  and  flow  cytometry 
(Figure 2a-c). Micromanipulation of individual cells using 
a transfer pipette has been used for isolating single cells 
from culture or liquid samples such as sperm, saliva or 
blood.  This  method  is  readily  accessible  but  labor 
intensive, and cells are subject to mechanical shearing. 
LCM allows single cells to be isolated directly from tissue 
sections,  making  it  desirable  for  clinical  applications. 
This  approach  requires  that  tissues  be  sectioned, 
mounted and stained so that they can be visualized to 
guide the isolation process. LCM has the advantage of 
allowing single cells to be isolated directly from morpho-
logical structures, such as ducts or lobules in the breast. 
Furthermore, tissue sections can be stained with fluor-
escent or chromogenic antibodies to identify specific cell 
types of interest. The disadvantage of LCM for genomic 
profiling is that some nuclei will inevitably be sliced in 
the course of tissue sectioning, causing loss of chromo-
some segments and generating artifacts in the data.
Flow  cytometry  using  fluorescence-activated  cell 
sorting (FACS) is by far the most efficient method for 
isolating  large  numbers  of  single  cells  or  nuclei  from 
liquid  suspensions.  Although  it  requires  sophisticated 
and expensive instrumentation, FACS is readily available 
at most hospitals and research institutions, and is used 
routinely  to  sort  cells  from  hematopoietic  cancers. 
Several  instruments  such  as  the  BD  Aria  II/III  (BD 
Biosciences,  San  Jose,  CA,  USA)  and  the  Beckman 
Coulter  MO-FLO  (Beckman  Coulter,  Brea,  CA,  USA) 
have been optimized for sorting single cells into 96-well 
Figure 1. Medical applications of single-cell sequencing. (a) Profiling of rare tumor cells in scarce clinical samples, such as fine-needle aspirates 
of breast lesions. (b) Isolation and profiling of circulating tumor cells in the blood. (c) Identification and profiling of rare chemoresistant cells before 
and after adjuvant therapy.
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advantage  that  cells  can  be  labeled  with  fluorescent 
antibodies  or  nuclear  stains  (4′,6-diamidino-2-phenyl 
indole dihydrochloride (DAPI)) and sorted into different 
fractions for downstream analysis.
Methods for single-cell genomic profiling
Several  methods  have  been  developed  to  measure 
genome-wide  information  of  single  cells,  including 
cytological approaches, aCGH and single-cell sequencing 
(Figure 2d-f). Some of the earliest methods to investigate 
the genetic information contained in single cells emerged 
in the 1970s in the fields of cytology and immunology. 
Cytological  methods  such  as  spectral  karyotyping, 
fluorescence  in  situ  hybridization  (FISH)  and  Giemsa 
staining enabled the first qualitative analysis of genomic 
rearrangements  in  single  tumor  cells  (illustrated  in 
Figure  2d).  In  the  1980s,  the  advent  of  PCR  enabled 
immunologists  to  investigate  genomic  rearrangements 
that occur in immunocytes, by directly amplifying and 
sequencing  DNA  from  single  cells  [20-22].  Together, 
these tools provided the first insight into the remarkable 
genetic  heterogeneity  that  characterizes  solid  tumors 
[23-28].
While  PCR  could  amplify  DNA  from  an  individual 
locus  in  a  single  cell,  it  could  not  amplify  the  entire 
Figure 2. Isolating single cells and techniques for genomic profiling. (a-c) Single-cell isolation methods. (d-f) Single-cell genomic profiling 
techniques. (a) Micromanipulation, (b) laser-capture microdissection (LCM), (c) fluorescence-activated cell sorting (FACS), (d) cytological methods to 
visualize chromosomes in single cells, (e) whole genome amplification (WGA) and microarray comparative genomic hybridization (CGH), (f) WGA 
and next-generation sequencing.
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using PCR-based strategies such as primer extension pre-
amplification [29] to amplify the genome of a single cell; 
however, these strategies were limited in coverage when 
applied to human genomes. A major milestone occurred 
with  the  discovery  of  two  DNA  polymerases  that 
displayed  remarkable  processivity  for  DNA  synthesis: 
Phi29  (Φ29)  isolated  from  the  Bacillus  subtilis 
bacteriophage, and Bst polymerase isolated from Bacillus 
stearothermophilus. Pioneering work in the early 2000s 
demonstrated  that  these  enzymes  could  amplify  the 
human  genome  over  1,000-fold  through  a  mechanism 
called multiple displacement amplification [30,31]. This 
approach,  called  whole  genome  amplification  (WGA), 
has  since  been  made  commercially  available  (New 
England Biolabs, Ipswich, MA, USA; QIAGEN, Valencia, 
CA, USA; Sigma-Aldrich, St Louis, MO, USA; Rubicon 
Genomics, Ann Arbor, MI, USA).
Coupling  WGA  with  array  CGH  enabled  several 
groups  to  begin  measuring  genomic  copy  number  in 
small  populations  of  cells,  and  even  single  cells 
(Figure 2e). These studies showed that it is possible to 
profile  copy  number  in  single  cells  in  various  cancer 
types, including CTCs [9,12,32], colon cancer cell lines 
[13] and renal cancer cell lines [14]. While pioneering, 
these studies were also challenged by limited resolution 
and  reproducibility.  However,  in  practice,  probe-based 
approaches such as aCGH microarrays are problematic 
for  measuring  copy  number  using  methods  such  as 
WGA,  where  amplification  is  not  uniform  across  the 
genome. WGA fragments amplified from single cells are 
sparsely distributed across the genome, representing no 
more than 10% of the unique human sequence [10]. This 
results  in  zero  coverage  for  up  to  90%  of  probes, 
ultimately leading to decreased signal to noise ratios and 
high standard deviations in copy number signal.
An alternative approach is to use NGS. This method 
provides  a  major  advantage  over  aCGH  for  measuring 
WGA  fragments  because  it  provides  a  non-targeted 
approach to sample the genome. Instead of differential 
hybridization  to  specific  probes,  sequence  reads  are 
integrated over contiguous and sequential lengths of the 
genome and all amplified sequences are used to calculate 
copy number. In a recently published study, we combined 
NGS with FACS and WGA in a method called single-
nucleus  sequencing  (SNS)  to  measure  high-resolution 
(approximately 50 kb) copy number profiles of single cells 
[10]. Flow-sorting of DAPI-stained nuclei isolated from 
tumor or other tissue permits deposition of single nuclei 
into individual wells of a multiwell plate, but, moreover, 
permits  sorting  cells  by  total  DNA  content.  This  step 
purifies normal nuclei (2N) from aneuploid tumor nuclei 
(not 2N), and avoids collecting degraded nuclei. We then 
use  WGA  to  amplify  the  DNA  from  each  well  by 
GenomePlex  (Sigma-Genosys,  The  Woodlands,  TX, 
USA) to yield a collection of short fragments, covering 
approximately 6% (mean 5.95%, SEM ± 0.229, n = 200) of 
the  human  genome  uniquely  [10],  which  are  then 
processed for Illumina sequencing (Illumina, San Diego, 
CA, USA) (Figure 3a). For copy number profiling, deep 
sequencing  is  not  required.  Instead,  the  SNS  method 
requires  only  sparse  read  depth  (as  few  as  2  million 
uniquely  mapped  76  bp  single-end  reads)  evenly 
distributed  along  the  genome.  For  this  application, 
Illumina  sequencing  is  preferred  over  other  NGS 
platforms  because  it  produces  the  highest  number  of 
short reads across the genome at the lowest cost.
To calculate the genomic copy number of a single cell, 
the sequence reads are grouped into intervals or ‘bins’ 
across the genome, providing a measure of copy number 
based on read density in each of 50,000 bins, resulting in 
a resolution of 50 kb across the genome. In contrast to 
previous  studies  that  measure  copy  number  from 
sequence read depth using fixed bin intervals across the 
human genome [33-37], we have developed an algorithm 
that  uses  variable  length  bins  to  correct  for  artifacts 
associates with WGA and mapping. The length of each 
bin  is  adjusted  in  size  based  on  a  mapping  simulation 
using  random  DNA  sequences,  depending  on  the 
expected unique read density within each interval. This 
corrects regions of the genome with repetitive elements 
(where fewer reads map), and biases introduced, such as 
GC content. The variable bins are then segmented using 
the  Kolmogorov-Smirnov  (KS)  statistical  test  [1,38]. 
Alternative  methods  for  sequence  data  segmentation, 
such  as  hidden  Markov  models,  have  been  developed 
[33], but have not yet been applied to sparse single-cell 
data. In practice, KS segmentation algorithms work well 
for  complex  aneuploid  cancer  genomes  that  contain 
many  variable  copy  number  states,  whereas  hidden 
Markov  models  are  better  suited  for  simple  cancer 
genomes  with  fewer  rearrangements,  and  normal 
individuals with fewer copy number states. To determine 
the  copy  number  states  in  sparse  single-cell  data,  we 
count the reads in variable bins and segments with KS, 
then use a Gaussian smoothed kernel density function to 
sample all of the copy number states and determine the 
ground  state  interval.  This  interval  is  used  to  linearly 
transform  the  data,  and  round  to  the  nearest  integer, 
resulting  in  the  absolute  copy  number  profile  of  each 
single  cell  [10].  This  processing  allows  amplification 
artifacts  associated  with  WGA  to  be  mitigated 
informatically,  reducing  biases  associated  with  GC 
content [9,14,39,40] and mapability of the human genome 
[41].  Other  artifacts,  such  as  over-replicated  loci 
(‘pileups’), as previously reported in WGA [40,42,43], do 
occur, but they are not at recurrent locations in different 
cells, and are sufficiently randomly distributed and sparse 
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when the mean interval size is 50 kb. While some WGA 
methods have reported the generation of chimeric DNA 
molecules in bacteria [44], these artifacts would mainly 
affect paired-end mappings of structural rearrangements, 
not single-end read copy number measurements that rely 
on sequence read depth. In summary, NGS provides a 
powerful tool to mitigate artifacts previously associated 
with quantifying copy number in single cells amplified by 
WGA, and eliminates the need for a reference genome to 
normalize  artifacts,  making  it  possible  to  calculate 
absolute copy number from single cells.
Clinical application of single-cell sequencing
While  single-cell  genomic  methods  such  as  SNS  are 
feasible in a research setting, they will not be useful in the 
clinic until advances are made in reducing the cost and 
time  of  sequencing.  Fortunately,  the  cost  of  DNA 
sequencing  is  falling  precipitously  as  a  direct  result  of 
industry  competition  and  technological  innovation. 
Sequencing has an additional benefit over microarrays in 
the potential for massive multiplexing of samples using 
barcoding strategies. Barcoding involves adding a specific 
4 to 6 base oligonucleotide sequence to each library as it 
is amplified, so that samples can be pooled together in a 
single sequencing reaction [45,46]. After sequencing, the 
reads  are  deconvoluted  by  their  unique  barcodes  for 
downstream analysis. With the current throughput of the 
Illumina HiSeq2000, it is possible to sequence up to 25 
single cells on a single-flow cell lane, thus allowing 200 
single cells to be profiled in a single run. Moreover, by 
decreasing  the  genomic  resolution  of  each  single-cell 
copy number profile (for example from 50 kb to 500 kb) it 
is possible to profile hundreds of cells in parallel on a 
Figure 3. Single-nucleus sequencing of breast tumors. (a) Single-nucleus sequencing involves isolating nuclei, staining with 4′,6-diamidino-2-
phenyl indole dihydrochloride (DAPI), flow-sorting by total DNA content, whole genome amplification (WGA), Illumina library construction, and 
quantifying genomic copy number using sequence read depth. (b) Phylogenetic tree constructed from single-cell copy number profiles of a 
monogenomic breast tumor. (c) Phylogenetic tree constructed using single-cell copy number profiles from a polygenomic breast tumor, showing 
three clonal subpopulations of tumor cells.
(a) (b)
(c)
0
2
4
6
8
10
12
0
1
2
3
0
0
1
2
3 4
5
WGA
Illumina libraries
C
o
p
y
 
n
u
m
b
e
r
4
5
20
10
30
40
10,000 20,000 30,000 40,000 50,000
Genomic position
E
u
c
l
i
d
e
a
n
 
d
i
s
t
a
n
c
e
(
a
r
b
i
t
r
a
r
y
 
u
n
i
t
s
)
E
u
c
l
i
d
e
a
n
 
d
i
s
t
a
n
c
e
(
a
r
b
i
t
r
a
r
y
 
u
n
i
t
s
)
Tumour
subpopulations
Tumour
subpopulations
Primary diploids
Primary aneuploids
1 100 Cell number
Monogenomic
Polygenomic
S1
S2
S3
S1
S2
S3
S4
S5
S6
Diploids
Hypodiploids
Aneuploid A
Aneuploid B
Cell number 1 53
Navin and Hicks Genome Medicine 2011, 3:31 
http://genomemedicine.com/content/3/5/31
Page 5 of 12single  lane,  or  thousands  on  a  run,  making  single-cell 
profiling economically feasible for clinical applications.
A major application of single-cell sequencing will be in 
the  detection  of  rare  tumor  cells  in  clinical  samples, 
where fewer than a hundred cells are typically available. 
These samples include body fluids such as lymph, blood, 
sputum, urine, or vaginal or prostate fluid, as well clinical 
biopsy samples such as fine-needle aspirates (Figure 1a) 
or core biopsy specimens. In breast cancer, patients often 
undergo  fine-needle  aspirates,  nipple  aspiration,  ductal 
lavages  or  core  biopsies;  however,  genomic  analysis  is 
rarely applied to these samples because of limited DNA 
or RNA. Early stage breast cancers, such as low-grade 
ductal carcinoma in situ (DCIS) or lobular carcinoma in 
situ,  which  are  detected  by  these  methods,  present  a 
formidable challenge to oncologists, because only 5% to 
10% of patients with DCIS typically progress to invasive 
carcinomas [47-51]. Thus, it is difficult for oncologists to 
determine  how  aggressively  to  treat  each  individual 
patient.  Studies  of  DCIS  using  immunohistochemistry 
support  the  idea  that  many  early  stage  breast  cancers 
exhibit  extensive  heterogeneity  [52].  Measuring  tumor 
heterogeneity in these scarce clinical samples by genomic 
methods may provide important predictive information 
on whether these tumors will evolve and become invasive 
carcinomas,  and  they  may  lead  to  better  treatment 
decisions by oncologists.
Early detection using circulating tumor cells
Another  major  clinical  application  of  single-cell 
sequencing  will  be  in  the  genomic  profiling  of  copy 
number  or  sequence  mutations  in  CTCs  and 
disseminated tumor cells (DTCs) (Figure 1b). Although 
whole  genome  sequencing  of  single  CTCs  is  not  yet 
technically  feasible,  with  future  innovations,  such  data 
may provide important information for monitoring and 
diagnosing  cancer  patients.  CTCs  are  cells  that 
intravasate into the circulatory system from the primary 
tumor, while DTCs are cells that disseminate into tissues 
such the bone. Unlike other cells in the circulation, CTCs 
often  contain  epithelial  surface  markers  (such  as 
epithelial  cell  adhesion  molecule  (EpCAM))  that  allow 
them to be distinguished from other blood cells. CTCs 
present  an  opportunity  to  obtain  a  non-invasive  ‘fluid 
biopsy’  that  would  provide  an  indication  of  cancer 
activity in a patient, and also provide genetic information 
that could direct therapy over the course of treatment. In 
a recent phase II clinical study, the presence of epithelial 
cells  (non-leukocytes)  in  the  blood  or  other  fluids 
correlated strongly with active metastasis and decreased 
survival in patients with breast cancer [53]. Similarly, in 
melanoma  it  was  shown  that  counting  more  than  two 
CTCs  in  the  blood  correlated  strongly  with  a  marked 
decrease in survival from 12 months to 2 months [54]. In 
breast  cancer,  DTCs  in  the  bone  marrow  (micro-
metastases) have also correlated with poor overall patient 
survival [55]. While studies that count CTCs or DTCs 
clearly have prognostic value, more detailed characteriza-
tion of their genomic lesions are necessary to determine 
whether they can help guide adjuvant or chemotherapy.
Several new methods have been developed to count the 
number of CTCs in blood, and to perform limited marker 
analysis on isolated CTCs using immunohistochemistry 
and FISH. These methods generally depend on antibodies 
against EpCAM to physically isolate a few epithelial cells 
from the nearly ten million non-epithelial leukocytes in a 
typical  blood  draw.  CellSearch  (Veridex,  LLC,  Raritan, 
NJ, USA) uses a series of immunomagnetic beads with 
EpCAM markers to isolate tumor cells and stain them 
with DAPI to visualize the nucleus. This system also uses 
CD45 antibodies to negatively select immune cells from 
the  blood  samples.  Although  CellSearch  is  the  only 
instrument that is currently approved for counting CTCs 
in  the  clinic,  a  number  of  other  methods  are  in 
development,  and  these  are  based  on  microchips  [56], 
FACS [57,58] or immunomagnetic beads [54] that allow 
CTCs  to  be  physically  isolated.  However,  a  common 
drawback of all methods is that they depend on EpCAM 
markers that are not 100% specific (antibodies can bind 
to surface receptors on blood cells) and the methods for 
distinguishing actual tumor cells from contaminants are 
not dependable [56].
Investigating the diagnostic value of CTCs with single-
cell sequencing has two advantages: impure mixtures can 
be resolved, and limited amounts of input DNA can be 
analyzed. Even a single CTC in an average 7.5 ml blood 
draw (which is often the level found in patients) can be 
analyzed to provide a genomic profile of copy number 
aberrations. By profiling multiple samples from patients, 
such  as  the  primary  tumor,  metastasis  and  CTCs,  it 
would be possible to trace an evolutionary lineage and 
determine the pathways of progression and site of origin.
Monitoring  or  detecting  CTCs  or  DTCs  in  normal 
patients  may  also  provide  a  non-invasive  approach  for 
the early detection of cancer. Recent studies have shown 
that many patients with non-metastatic primary tumors 
show evidence of CTCs [53,59]. While the function of 
these  cells  is  largely  unknown,  several  studies  have 
demonstrated  prognostic  value  of  CTCs  using  gene-
specific  molecular  assays  such  as  reverse  transcriptase 
(RT)-PCR  [60-62].  Single-cell  sequencing  could  greatly 
improve  the  prognostic  value  of  such  methods  [63]. 
Moreover, if CTCs generally share the mutational profile 
of the primary tumors (from which they are shed), then 
they could provide a powerful non-invasive approach to 
detecting  early  signs  of  cancer.  One  day,  a  general 
physician may be able to draw a blood sample during a 
routine  check-up  and  profile  CTCs  indicating  the 
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these genomic profiles reveal mutations in cancer genes, 
then  medical  imaging  (magnetic  resonance  imaging  or 
computed tomography) could be pursued to identify the 
primary  tumor  site  for  biopsy  and  treatment.  CTC 
monitoring  would  also  have  important  applications  in 
monitoring  residual  disease  after  adjuvant  therapy  to 
ensure that the patients remain in remission.
The analysis of scarce tumor cells may also improve the 
early  detection  of  cancers.  Smokers  could  have  their 
sputum screened on regular basis to identify rare tumor 
cells  with  genomic  aberrations  that  provide  an  early 
indication  of  lung  cancer.  Sperm  ejaculates  contain  a 
significant amount of prostate fluid that may contain rare 
prostate cancer cells. Such cells could be purified from 
sperm  using  established  biomarkers  such  as  prostate-
specific  antigen  [64]  and  profiled  by  single-cell 
sequencing.  Similarly,  it  may  be  possible  to  isolate 
ovarian cancer cells from vaginal fluid using established 
biomarkers, such as ERCC5 [65] or HE4 [66], for genomic 
profiling. The genomic profile of these cells may provide 
useful information on the lineage of the cell and from 
which organ it has been shed. Moreover, if the genomic 
copy  number  profiles  of  rare  tumor  cells  accurately 
represent the genetic lesions in the primary tumor, then 
they  may  provide  an  opportunity  for  targeted  therapy. 
Previous work has shown that classes of genomic copy 
number profiles correlate with survival [18], and thus the 
profiles of rare tumor cells may have predictive value in 
assessing the severity of the primary cancer from which 
they have been shed.
Investigating tumor heterogeneity with SNS
Tumor  heterogeneity  has  long  been  reported  in 
morphological [67-70] and genetic [26,28,71-76] studies 
of solid tumors, and more recently in genomic studies 
[1-3,10,77-81],  transcriptional  profiles  [82,83]  and 
protein  levels  [52,84]  of  cells  within  the  same  tumor 
(summarized in Table 1). Heterogeneous tumors present 
a  formidable  challenge  to  clinical  diagnostics,  because 
sampling single regions within a tumor may not represent 
the  population  as  a  whole.  Tumor  heterogeneity  also 
confounds  basic  research  studies  that  investigate  the 
fundamental basis of tumor progression and evolution. 
Most current genomic methods require large quantities 
of input DNA, and thus their measurements represent an 
average signal across the population. In order to study 
tumor subpopulations, several studies have stratified cells 
using regional macrodissection [1,2,79,85], DNA ploidy 
[1,86],  LCM  [78,87]  or  surface  receptors  [3]  prior  to 
applying genomic methods. While these approaches do 
increase the purity of the subpopulations, they remain 
admixtures. To fully resolve such complex mixtures, it is 
necessary to isolate and study the genomes of single cells.
In the single-cell sequencing study described above, we 
applied SNS to profile hundreds of single cells from two 
primary  breast  carcinomas  to  investigate  substructure 
and  infer  genomic  evolution  [10].  For  each  tumor  we 
quantified  the  genomic  copy  number  profile  of  each 
single cell and constructed phylogenetic trees (Figure 3). 
Our  analysis  showed  that  one  tumor  (T16)  was 
monogenomic, consisting of cells with tightly conserved 
copy number profiles throughout the tumor mass, and 
was  apparently  the  result  of  a  single  major  clonal 
expansion  (Figure  3b).  In  contrast,  the  second  breast 
tumor  (T10)  was  polygenomic  (Figure  3c),  displaying 
three major clonal subpopulations that shared a common 
genetic  lineage.  These  subpopulations  were  organized 
into  different  regions  of  the  tumor  mass:  the  H 
subpopulation occupied the upper sectors of the tumor 
(S1  to  S3),  while  the  other  two  tumor  subpopulations 
(AA and AB) occupied the lower regions (S4 to S6). The 
AB tumor subpopulation in the lower regions contained 
a  massive  amplification  of  the  KRAS  oncogene  and 
homozygous deletions of the EFNA5 and COL4A5 tumor 
suppressors. When applied to clinical biopsy or tumor 
samples, such phylogenetic trees are likely to be useful 
for  improving  the  clinical  sampling  of  tumors  for 
diagnostics, and may eventually aid in guiding targeted 
therapies for the patient.
Response to chemotherapy
Tumor heterogeneity is likely to play an important role in 
the response to chemotherapy [88]. From a Darwinian 
perspective,  tumors  with  the  most  diverse  allele 
frequencies will have the highest probability of surviving 
a  catastrophic  selection  pressure  such  as  a  cytotoxic 
agent  or  targeted  therapy  [89,90].  A  major  question 
revolves around whether resistant clones are pre-existing 
in  the  primary  tumor  (prior  to  treatment)  or  whether 
they emerge in response to adjuvant therapy by acquiring 
de  novo  mutations.  Another  important  question  is 
whether heterogeneous tumors generally show a poorer 
response to adjuvant therapy. Using samples of millions 
of cells, recent studies in cervical cancer treated with cis-
platinum  [79]  and  ovarian  carcinomas  treated  with 
chemoradiotherapy [91] have begun to investigate these 
questions by profiling tumors for genomic copy number 
before  and  after  treatment.  Both  studies  reported 
detecting some heterogeneous tumors with pre-existing 
resistant  subpopulations  that  expanded  further  after 
treatment.  However,  since  these  studies  are  based  on 
signals derived from populations of cells, their results are 
likely  to  underestimate  the  total  extent  of  genomic 
heterogeneity  and  frequency  of  resistant  clones  in  the 
primary  tumors.  These  questions  are  better  addressed 
using single-cell sequencing methods, because they can 
provide  a  fuller  picture  of  the  extent  of  genomic 
Navin and Hicks Genome Medicine 2011, 3:31 
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genomic  heterogeneity  may  itself  provide  useful 
prognostic  information,  guiding  patients  who  are 
deciding  on  whether  to  elect  chemotherapy  and  the 
devastating  side-effects  that  often  accompany  it.  In 
theory, patients with monogenomic tumors will respond 
better and show better overall survival compared with 
patients  with  polygenomic  tumors,  which  may  have  a 
higher  probability  of  developing  or  having  resistant 
clones,  that  is,  more  fuel  for  evolution.  Single-cell 
sequencing  can  in  principle  also  provide  a  higher 
sensitivity  for  detecting  rare  chemoresistant  clones  in 
primary tumors (Figure 1c). Such methods will enable the 
research community to investigate questions of whether 
resistant  clones  are  pre-existing  in  primary  tumors  or 
arise  in  response  to  therapies.  Furthermore,  by 
multiplexing and profiling hundreds of single cells from a 
patient’s  tumor,  it  will  possible  to  develop  a  more 
comprehensive picture of the total genomic diversity in a 
tumor before and after adjuvant therapy.
Future directions
Single-cell sequencing methods such as SNS provide an 
unprecedented  view  of  the  genomic  diversity  within 
tumors and provide the means to detect and analyze the 
genomes  of  rare  cancer  cells.  While  cancer  genome 
Table 1. Summary of tumor heterogeneity studies
Cancer  Heterogeneity  Method  Details  Reference
Lung  Morphology  H&E staining  Microscopic examination  [67]
Pancreas  Morphology  H&E staining  Microscopic examination  [68]
Prostate  Morphology  H&E staining  Microscopic examination  [69]
Bladder  Morphology  H&E staining  Microscopic examination  [70]
Glioma  DNA  G-banding  G-banding and ploidy  [23]
Breast  DNA  G-banding  Karyotype G-banding   [25]
Breast  DNA  G-banding  Karyotype G-banding   [27]
Breast  DNA  G-banding  Karyotype G-banding   [94]
Bladder  DNA  FISH  DNA copy number analysis   [26]
Breast  DNA  FISH  DNA copy number analysis   [72]
Pancreas  DNA  FISH  DNA copy number analysis   [74]
Neuroblastoma  DNA  FISH  DNA copy number analysis   [73]
Breast  DNA  FISH  DNA copy number analysis   [28]
Multiple myeloma  DNA  FISH  DNA copy number analysis   [75]
Esophagus  DNA  FISH  FISH, LOH, microsatellites, sequencing  [76]
Breast  DNA  FISH  DNA copy number analysis   [71]
Breast (DCIS)  Protein  IHC  IHC using antibodies  [52]
Breast  Protein  MS  MS and LCM  [84]
Prostate  RNA  Expression  Transcriptional microarrays  [82]
Cervix  RNA  Expression  Transcriptional microarrays  [83]
Breast  DNA  CGH  LCM and BAC-CGH  [78]
Breast  DNA  CGH  Receptor-purification and SNP microarrays  [3]
Breast  DNA  CGH  Sectoring and aCGH  [2]
Breast  DNA  CGH  Sectoring, ploidy and aCGH  [1]
Cervix  DNA  CGH  Regional macrodissection and aCGH  [79]
Breast  DNA  NGS  NGS  [80]
Breast  DNA  NGS  NGS  [81]
Pancreas  DNA  NGS  Sectoring and NGS  [77]
Breast  DNA  NGS  Single-nucleus sequencing  [10]
Summary of studies that have detected intratumor heterogeneity using various techniques, at the DNA, RNA and protein level. aCGH, microarray comparative 
genomic hybridization; BAC-CGH, bacterial artificial chromosome-comparative genomic hybridization; CGH, comparative genomic hybridization; DCIS, ductal 
carcinoma in situ; FISH, fluorescence in situ hybridization; H&E, hematoxylin and eosin; IHC, immunohistochemistry; LCM, laser-capture microdissection; LOH, loss of 
heterozygosity; MS, mass spectrometry; NGS, next-generation sequencing.
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spectrum  of  mutations  that  occur  within  a  patient 
[81,92], they cannot determine whether all of the tumor 
cells  contain  the  full  set  of  mutations,  or  alternatively 
whether  different  subpopulations  contain  subsets  of 
these  mutations  that  in  combination  drive  tumor 
progression.  Moreover,  single-cell  sequencing  has  the 
potential  to  greatly  improve  our  fundamental 
understanding  of  how  tumors  evolve  and  metastasize. 
While  single-cell  sequencing  methods  using  WGA  are 
currently limited to low coverage of the human genome 
(approximately  6%),  emerging  third-generation 
sequencing  technologies  such  as  that  developed  by 
Pacific  Biosystems  (Lacey,  WA,  USA)  [93]  may  greatly 
improve  coverage  through  single-molecule  sequencing, 
by requiring lower amounts of input DNA.
In summary, the future medical applications of single-
cell  sequencing  will  be  in  early  detection,  monitoring 
CTCs  during  treatment  of  metastatic  patients,  and 
measuring the genomic diversity of solid tumors. While 
pathologists  can  currently  observe  thousands  of  single 
cells from a cancer patient under the microscope, they 
are limited to evaluating copy number at a specific locus 
for  which  FISH  probes  are  available.  Genomic  copy 
number  profiling  of  single  cells  can  provide  a  fuller 
picture of the genome, allowing thousands of potentially 
aberrant cancer genes to be identified, thereby providing 
the oncologist with more information on which to base 
treatment  decisions.  Another  important  medical 
application  of  single-cell  sequencing  will  be  in  the 
profiling  of  CTCs  for  monitoring  disease  during  the 
treatment of metastatic disease. While previous studies 
have  shown  value  in  the  simple  counting  of  epithelial 
cells in the blood [53,54], copy number profiling of single 
CTCs may provide a fuller picture, allowing clinicians to 
identify  genomic  amplifications  of  oncogenes  and 
deletions of tumor suppressors. Such methods will also 
allow  clinicians  to  monitor  CTCs  over  time  following 
adjuvant or chemotherapy, to determine if the tumor is 
likely to show recurrence.
The  major  challenge  ahead  for  translating  single-cell 
methods  into  the  clinic  will  be  the  innovation  of 
multiplexing strategies to profile hundreds of single cells 
quickly  and  at  a  reasonable  cost.  Another  important 
aspect  is  to  develop  these  methods  for  paraffin-
embedded  tissues  (rather  than  frozen),  since  many 
samples  are  routinely  processed  in  this  manner  in  the 
clinic.  When  future  innovations  allow  whole  genome 
sequencing of single tumor cells, oncologists will also be 
able  to  obtain  the  full  spectrum  of  genomic  sequence 
mutations in cancer genes from scarce clinical samples. 
However, this remains a major technical challenge, and is 
likely  to  be  the  intense  focus  of  both  academia  and 
industry in the coming years. These methods are likely to 
improve all three major themes of medicine: prognostics, 
diagnostics and chemotherapy, ultimately improving the 
treatment and survival of cancer patients.
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